Medicina
Facultat
JUAN
GÓMEZ-REINO CARNOTA
Investigador fins a 2007
Publicacions en què col·labora amb JUAN GÓMEZ-REINO CARNOTA (179)
2022
-
Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review
Seminars in Arthritis and Rheumatism, Vol. 52
2019
-
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLoS ONE, Vol. 14, Núm. 2
-
Specific Association of HLA–DRB1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis
Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 331-339
2018
-
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)
Clinical Microbiology and Infection, Vol. 24, pp. S10-S20
-
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224
-
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLoS ONE, Vol. 13, Núm. 5
2016
-
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140
2015
-
Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide
Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294
-
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors
Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345
-
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study
Arthritis Research and Therapy, Vol. 17, Núm. 1
2014
-
Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis
Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 238-245
-
Documento práctico para el uso de abatacept subcutáneo
Reumatologia Clinica, Vol. 10, Núm. 4, pp. 218-226
-
Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus
Arthritis Research and Therapy, Vol. 16, Núm. 3
-
Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study
Arthritis Research and Therapy, Vol. 16, Núm. 1
-
Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis
Arthritis Research and Therapy, Vol. 16, Núm. 2
2013
-
Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico
Reumatologia Clinica, Vol. 9, Núm. 5, pp. 281-296
-
El uso de abatacept en artritis reumatoide: Revisión de la evidencia y recomendaciones
Reumatologia Clinica, Vol. 9, Núm. 1, pp. 5-17
2012
-
Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: A case-control study
Arthritis Research and Therapy, Vol. 14, Núm. 2
-
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study
Annals of the Rheumatic Diseases, Vol. 71, Núm. 11, pp. 1861-1864
-
Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study
PLoS ONE, Vol. 7, Núm. 9